3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
111
Triple Negative Breast Neoplasms
25
Lung Neoplasms
8
Pancreatic Neoplasms
6
Neoplasm Metastasis
6
Colonic Neoplasms
6
Ovarian Neoplasms
5
Neoplasms
5
Melanoma
5
Colorectal Neoplasms
5
Stomach Neoplasms
4
Head and Neck Neoplasms
4
Esophageal Neoplasms
4
Sarcoma
3
Liver Neoplasms
3
Kidney Neoplasms
3
Cholangiocarcinoma
3
Uterine Cervical Neoplasms
2
Multiple Myeloma
2
Motor Activity
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Laryngeal Neoplasms
2
Gastrointestinal Neoplasms
2
Fatigue
2
Fallopian Tube Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Brain Neoplasms
2
Bile Duct Neoplasms
2
Interventions
Fulvestrant
10
Letrozole
4
Alpelisib
4
ribociclib
3
palbociclib
3
Paclitaxel
2
NVP-BKM120
2
volagidemab
1
serabelisib
1
sapanisertib
1
olaparib
1
liposomal doxorubicin
1
gedatolisib
1
exemestane
1
dapagliflozin
1
capivasertib
1
abemaciclib
1
Taxes
1
Tamoxifen
1
Secretin
1
STX-478
1
Metformin
1
Lomustine
1
Leuprolide
1
Irinotecan
1
Imlunestrant
1
Goserelin
1
Gemcitabine
1
Drug Therapy
1
Doxorubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hereditary Sensory and Autonomic Neuropathies
×
Drug Therapy
×
Breast
×
Clear all
NCT03386162
2022-11-28
SAFIR-PI3K
UNICANCER
Phase 2
Terminated
31 enrolled